NXP900 plus osimertinib for advanced EGFR‑mutant non‑small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open‑label Phase 1b trial gives adults with unresectable or metastatic EGFR‑mutated NSCLC an experimental agent called NXP900 in combination with standard osimertinib. Eligible participants have disease that progressed on prior osimertinib and must have ECOG performance status 0–1 with no other known oncogenic driver alterations. The trial primarily focuses on safety, tolerability, and establishing dosing for the combination while also collecting preliminary evidence of anti‑tumor activity. Treatment and follow‑up visits are conducted at participating cancer centers with regular clinical assessments and imaging.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provide written informed consent.
2. 18 years old or older.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.

Exclusion Criteria:

1. Subject's cancer has a known oncogenic driver alteration other than EGFR.
2. Known EGFR mutations that cause resistance to osimertinib
3. Known human epidermal growth factor receptor 2 (HER2) overexpression
4. Any contraindications to treatment with osimertinib

Where it's running

• Maryland Oncology Hematology
  Calverton, Maryland, United States Recruiting
• Willamette Valley Cancer Institute and Research Center
  Eugene, Oregon, United States Recruiting
• UPMC Hillman Cancer Center
  Pittsburgh, Pennsylvania, United States Recruiting
• NEXT Houston
  Houston, Texas, United States Recruiting
• NEXT Virginia
  Fairfax, Virginia, United States Recruiting
• Massachusetts General Hospital
  Boston, Massachusetts, United States Not yet recruiting

Study contacts

• Principal investigator: Zofia Piotrowska, MD, MHS — Massachusetts General Hospital
• Study coordinator: Erin Belshaw
• Email: ebelshaw@nuvectis.com
• Phone: 12016278129

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Osimertinib with Cyclosporine A for EGFR-mutant NSCLC

  This phase II study tests whether adding cyclosporine A to osimertinib helps people with EGFR-mutant metastatic NSCLC who still have detectable tumor DNA in blood.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07874490

• Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic NSCLC

  This trial tests whether surgically removing the main lung tumor, after initial osimertinib therapy, helps people with EGFR-mutant oligometastatic non-small cell lung cancer live longer without disease progression.

  Recruiting Phase 3 National Taiwan University Hospital · Taipei, Taipei City · NCT07738172

• Izalontamab Brengitecan with Osimertinib in EGFR-mutant NSCLC: first-line versus standard options

  This study tests whether adding iza-bren to osimertinib can help people with newly diagnosed EGFR-mutant non-small cell lung cancer, compared with osimertinib alone or osimertinib plus platinum-based chemotherapy.

  Recruiting at 10 sites Phase 3 Bristol-Myers Squibb · Beverly Hills, California and 204 other locations · NCT07680790

• BL-B01D1 with Osimertinib before/around surgery for EGFR-mutant resectable NSCLC

  A Phase II/III trial tests if adding BL-B01D1 to osimertinib around surgery helps people with resectable EGFR-mutant non-small cell lung cancer.

  Recruiting at 2 sites Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07642024

• BL-B01D1 plus osimertinib vs osimertinib alone in unresectable EGFR-mutated NSCLC (Stage III) after chemoradiation

  This trial tests whether adding BL-B01D1 to osimertinib helps people with unresectable Stage III EGFR-mutated non-small cell lung cancer who did not progress after platinum-based chemoradiation.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07640789

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.